Sign Out
In order to avoid the emergence of resistant bacteria, bacterial susceptibility should be confirmed and treatment with Cravit Ophth Soln should be limited to minimum period required for the eradication of infection.
The efficacy of Cravit Ophth Soln to methicillin-resistant Staphylococcus aureus (MRSA) has not been proven. Therefore, other drugs having a potent anti-MRSA activity should be administered immediately to patients positively infected with MRSA and not showing any improvement of symptoms with Cravit Ophth Soln.
Use in pregnancy: Cravit Ophth Soln should be used in pregnant women or women who may possibly be pregnant only if the expected therapeutic benefits are judged to outweigh the possible risks associated with treatment. The safety of Cravit Ophth Soln during pregnancy has not been established.
